By Pharmaceutical Technology –
Regenerative medicine offers an innovative approach to treating different indications by restoring damaged or diseased cells and tissues.
Following several years of limited activity, FDA approvals for regenerative medicines have accelerated, culminating in a record eight approvals in 2024. Recent findings also highlighted a surge in regenerative medicine advanced therapy (RMAT) designations, which, together with a robust late-stage pipeline, suggests FDA approval activity for regenerative medicine products is likely to remain elevated in the coming years.
